GGrantIndex
← Leaderboards

Diane M Puccetti

University Of Wisconsin Madison

$719,707
Attributed
$719,707
Total exposure
5
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$719,707 · 5

By mechanism

M01$719,707 · 5

Top collaborators

No co-investigators on record.

Most similar at University Of Wisconsin Madison

Same institution · by research overlap

Others in their field

Top investigators on “Child (0-11)

Research focus

Child (0-11)Human SubjectNeoplasm /Cancer ChemotherapyClinical ResearchCombination ChemotherapyDrug Screening /EvaluationHuman Therapy EvaluationOral AdministrationMethotrexateAntineoplasticsAcute Lymphocytic LeukemiaCortisolVincristineAdolescence (12-20)Cis Platinum CompoundCognitionCyclophosphamideHodgkin'S DiseaseHuman MorbidityHuman MortalityLomustineMedulloblastomaNeoplasm /Cancer Radiation TherapyNeoplasm /Cancer Relapse /Recurrence

Grant awards (18)

Oral MP vs. Oral TG and IT MTX vs. IT MTX/Cytarabine/Hydrocortisone for SR-ALL$41,542
M01 · FY2004 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$106,600
M01 · FY2002 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$106,600
M01 · FY2002 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$106,600
M01 · FY2002 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$106,600
M01 · FY2001 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$106,600
M01 · FY2001 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$106,600
M01 · FY2001 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$12,855
M01 · FY2001 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$12,855
M01 · FY2001 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$12,855
M01 · FY2001 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$0
M01 · FY2000 · RR
DOCETAXEL (TAXOTERE) IN CHILDREN WITH RECURRENT SOLID TUMORS$0
M01 · FY2000 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$0
M01 · FY2000 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$0
M01 · FY2000 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$0
M01 · FY2000 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$0
M01 · FY2000 · RR
DOCETAXEL (TAXOTERE) IN CHILDREN WITH RECURRENT SOLID TUMORS$0
M01 · FY2000 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$0
M01 · FY2000 · RR